The Population Council's microbicide gel MZC (also known as PC-1005) containing MIV-150 and zinc acetate dihydrate (ZA) in carrageenan (CG) has shown promise as a broad-spectrum microbicide against HIV, herpes simplex virus (HSV), and human papillomavirus. Previous data show antiviral activity against these viruses in cell-based assays, prevention of vaginal and rectal simianhuman immunodeficiency virus reverse transcriptase (SHIV-RT) infection, and reduction of vaginal HSV shedding in rhesus macaques and also excellent antiviral activity against HSV and human papillomavirus in murine models. Recently, we demonstrated that MZC is safe and effective against SHIV-RT in macaque vaginal explants. Here we established models of ex vivo SHIV-RT/HSV-2 coinfection of vaginal mucosa and SHIV-RT infection of rectal mucosa in macaques (challenge of rectal mucosa with HSV-2 did not result in reproducible tissue infection), evaluated antiviral activity of MZC, and compared quantitative polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay readouts for monitoring SHIV-RT infection. MZC (at nontoxic dilutions) significantly inhibited SHIV-RT in vaginal and rectal mucosas and HSV-2 in vaginal mucosa when present during viral challenge. Analysis of SHIV-RT infection and MZC activity by 1-step simian immunodeficiency virus gag quantitative RT-PCR and p27 enzyme-linked immunosorbent assay demonstrated similar virus growth dynamics and MZC activity by both methods and higher sensitivity of quantitative RT-PCR. Our data provide more evidence that MZC is a promising dual compartment multipurpose prevention technology candidate.
INTRODUCTION
More than 2 decades ago, an "epidemiological synergy" between HIV-1 and other sexually transmitted infections (STIs) increasing the risk of HIV-1 acquisition was suggested. 1 Among STIs affecting HIV transmission and pathogenesis, noncurable STIs like herpes simplex virus 2 (HSV-2) and human papillomavirus (HPV) deserve special attention. Recent studies reported up to 3-and 7-fold increased risk of HIV-1 transmission with prevalent and incident HSV-2 infection, respectively. [2] [3] [4] [5] HIV-1/HSV-2 coinfection affects the pathogenesis of both viruses, being associated with increased HIV-1 viral load [6] [7] [8] and HSV-2 shedding quantity and frequency. [9] [10] [11] HSV-2 plays a significant role promoting HIV transmission and acquisition in sub-Saharan Africa, where HSV-2 may account for 25%-35% of incident HIV infections. 12 Importantly, studies in rhesus macaques (RM) showed that vaginal HSV-2 infection is associated with increased susceptibility to the simian/human immunodeficiency virus (SHIV) SF162P3 and provided some insights into possible mechanisms of increased transmission. 13 Specifically, frequency of vaginal CD4 + T cells expressing high level of a4b7, a gut-homing integrin that binds gp120 14 and facilitates HIV/simian immunodeficiency virus (SIV) infection, [13] [14] [15] [16] [17] [18] is increased in HSV-2-infected RM. 13 An increase of a4b7 high CD4 + T cells in rectal mucosa was also observed in rectal HSV-2 infection in RM. 19 Similar to HSV-2, HPV infection is associated with an increase of HIV-1 acquisition 20 and HIV-1 positivity is associated with increased HPV prevalence [21] [22] [23] and incidence. 24, 25 The development of multipurpose prevention technologies active against HIV-1, HSV-2, and HPV vaginally and rectally could significantly improve global public health. 20, [26] [27] [28] The Population Council's gel containing 50 mM of the nonnucleoside reverse transcriptase inhibitor MIV-150 and 14 mM zinc acetate dihydrate (ZA) in carrageenan (CG) (MZC) demonstrated activity against vaginal SHIV reverse transcriptase (RT) (RM), vaginal HSV-2 (RM, mice), anorectal HSV-2 (mice), and vaginal and anorectal HPV (mice). [29] [30] [31] [32] [33] [34] [35] MZC protects against SHIV-RT in RM vaginal explants 36, 37 26 Here we aimed to establish vaginal and rectal explant SHIV-RT/HSV-2 coinfection models for microbicide testing and assess the activity of MZC against both viruses in these models. Traditionally, infection with HIV and SIV/SHIV in explants is monitored by p24 and p27 enzyme-linked immunosorbent assays (ELISAs). 36, [39] [40] [41] [42] Here we explored whether analysis of accumulation of viral RNA can be used as an alternative for p27 ELISA.
MATERIALS AND METHODS

Macaques
Naive, SHIV-RT-, SIV-, and HSV-1-exposed uninfected/ infected Chinese and Indian RMs (Macaca mulatta) were used. Macaques were housed at the Tulane National Primate Research Center (TNPRC, Covington, LA), accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC no. 000594). The use of macaques was approved by the Animal Care and Use Committee of the TNPRC (OLAW assurance no. A4499-01), and animal care complied with the regulations in the Animal Welfare Act 43 and the Guide for the Care and Use of Laboratory Animals. 44 All vaginal and rectal biopsy procedures were performed by board-certified veterinarians (American College of Laboratory Animal Medicine). The biopsies were collected not more often than every 4 weeks. Anesthesia was administered before and during all procedures, and analgesics were provided afterward as previously described. 29, 45 Necropsy tissues were available from 9 animals. These animals were euthanized using methods consistent with recommendations of the American Veterinary Medical Association Guidelines for Euthanasia. The animals were anesthetized with tiletamine-zolazepam (each at 4 mg/kg intramuscularly) and given buprenorphine (0.01 mg/kg intramuscularly) followed by an overdose of pentobarbital sodium. Death was confirmed by auscultation of the heart and pupillary dilation.
Gels
The components of MZC and CG gels are summarized in Table 1 .
Viral Stocks
SHIV-RT was generated from the original stock provided by Disa Böttiger (Medivir AB, Sweden) 46 using phytohaemagglutinin (PHA)/interleukin-2 (IL-2)-activated macaque peripheral blood mononuclear cells and titered in CEMx174 cells before use. 29 HSV-2 strain G was generated as described previously. 47 Briefly, HSV-2 strain G was propagated in Vero cells American Type Culture Collection (ATCC) 48 as described earlier, 49 and the viral titer in plaque-forming units (pfu)/mL was obtained by plaque formation assay on monolayer cultures of Vero cells. 50 
Macaque Tissue Processing
Vaginal mucosa (n = 2, 3 · 5 mm biopsies procured at each collection time; or necropsy tissues) was obtained from RM. Tissues were transported overnight and cut into 3 · 3 mm explants as described previously 36, 51 before viral challenge (below). Rectal mucosa (n = 15-20, 1.5 · 1.5 mm biopsies procured at each collection time) was processed for viral challenge (below) at TNPRC immediately after collection.
Tissue Viability
To assess tissue viability after overnight (;18 hours) exposure to MZC or CG gels, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay was performed as previously described. 36, 51 Comparison of SHIV-RT Growth Kinetics Using Quantitative RT Polymerase Chain Reaction and p27 ELISA To compare SHIV-RT infection readout methods in vaginal explants, tissues were processed and challenged with SHIV-RT as previously described. 36 Briefly, vaginal explants were stimulated [5 mg/mL PHA (Sigma Aldrich) and 100 U/mL IL-2 (NCI BRB Preclinical Repository, Frederick, MD)] for 48 hours and then challenged with 10 4 TCID 50 SHIV-RT per explant for ;18 hours. After washout, explants were cultured in the presence of IL-2 for 14 days. 36 Supernatants were collected on days 0, 3, 7, 11, and 14, and infection levels were analyzed by SIV gag one-step quantitative RT polymerase chain reaction (qRT-PCR) and p27 ELISA. To compare SHIV-RT infection readout methods in rectal biopsies, supernatants from SHIV-RT/HSV-2 cochallenge experiments (below) were used. Controls included 10 mM 3TC or 10 mM 3TC/100 mg/mL Acyclovir. 
SHIV-RT and HSV-2 Cochallenge of Vaginal and Rectal Mucosae and Antiviral Activity of MZC
PHA/IL-2-stimulated vaginal explants and unstimulated rectal biopsies were cochallenged with 10 4 TCID 50 SHIV-RT and 10 6 pfu HSV-2 per explant for ;18 (vaginal) or 4 hours (rectal). To test the antiviral activity of MZC, viral challenge was done in the presence of 1:300 and/or 1:100 diluted MZC and CG gels vs. untreated (medium) and 3TC/Acyclovir controls. After washout, vaginal explants were cultured in the presence of IL-2 for 14 days. 36 Rectal biopsies (n = 4) were placed on 12-mm diameter Gelfoam sponges (Ethicon, Somerville, NJ) presoaked in complete DMEM (cDMEM) (DMEM Cellgro Mediatech) containing 10% fetal bovine serum (Gibco; Life Technologies, Grand Island, NY), 100 U/mL penicillin, 100 mg/mL streptomycin (Cellgro Mediatech), and 100 mM Eagle's minimum essential medium (MEM) nonessential amino acids (Irvine Scientific, Santa Ana, CA) at 37°C, 5% CO 2 , for at least 30 minutes and cultured for 14 days (no IL-2). Rectal biopsies were cultured in cDMEM to which 80 mg/mL gentamicin had been added (Gibco). Supernatants from both vaginal and rectal tissues were collected on days 0, 3, 7, 11, and 14, and levels of infections were analyzed by qPCR and/or ELISA.
qPCR and qRT-PCR
Five microliters of tissue culture supernatants were analyzed using the KAPA SYBR FAST Universal one-Step qRT-PCR kit (Kapa Biosystems, Wilmington, MA) for the quantification of SIV gag copies and the KAPA SYBR FAST Universal qPCR assay (Kapa Biosystems) for the quantification of HSV pol copies with the Viia 7 real-time PCR system (Applied Biosystems, Carlsbad, CA).
Primers for SIV were 59-GGTTGCACCCCCTATGA-CAT-39 (SIV667gag Fwd) and 59-TGCATAGCCGCTT-GATGGT-39 (SIV731gag Rev). Results were analyzed by the standard curve method, using SIV mac1A11 DNA obtained from Primers for HSV-2 pol were 59-GCTCGAGTGC-GAAAAAACGTTC-39
(HSV-2pol Fwd) and 59-TGCGGTTGATAAACGCGCAGT-39 (HSV-2pol Rev). 13, 53 For the generation of HSV-2-positive control plasmid, a 2.6-kb fragment of the HSV-2 UL30 gene was amplified by PCR using the iProof High-Fidelity DNA Polymerase (BioRad, Hercules, CA). Genomic DNA template was prepared from HSV-2 stock, and primers 59-GACGAGCGCGACGTCCTC-39 (Fwd) and 59-TCGTCGTAAAACAGCAGGTC-39 (Rev) were used. The PCR product was cloned into the pCR Blunt II TOPO vector (Life Technologies) and the construct verified by sequencing.
p27 ELISA p27 content in tissue culture supernatants was measured by RETRO-TEK SIV p27 Antigen ELISA kit (ZeptoMetrix, Buffalo, NY).
Statistical Analyses
The sensitivity of paired p27 ELISA and SIV gag qRT-PCR results was compared using McNemar test and interrater agreement (Kappa) statistics using GraphPad calculators available online (graphpad.com).
Analysis of tissue viability (MTT assay) was performed as described earlier 36 using a log-normal generalized linear mixed model predicting the weight-normalized optical density (OD) 570 of each replicate.
Analysis of gel activity against SHIV-RT and HSV-2 was performed as described previously 36, 37, 39, 40, 54 
All analyses were performed with SAS V9.4 and SAS/ STAT V13.1 with a = 0.05. Significant P values of ,0.05 (*), ,0.01 (**), and #0.001 (***) are indicated.
RESULTS
SIV gag qRT-PCR and p27 ELISA Demonstrate Similar SHIV-RT Growth Kinetics in Explants With qRT-PCR Being a More Sensitive Infection Readout
To determine the feasibility of one-step SIV gag qRT-PCR for analysis of SHIV-RT infection in vaginal and rectal tissue cultures, a comparison with p27 ELISA was carried out.
Supernatants from vaginal (n = 7 experiments) and rectal (n = 8 experiments) tissues challenged with SHIV-RT (vaginal) or SHIV-RT and HSV-2 (rectal) were analyzed by both ELISA and qRT-PCR at 5 time points postchallenge (days 0, 3, 7, 11, and 14). 3TC and 3TC/Acyclovir controls were available in n = 2 vaginal tissue experiments and in all n = 8 rectal tissue experiments, respectively. The results show similar SHIV-RT growth kinetics by both methods (Fig. 1) (Table 2) . These results further emphasize higher sensitivity of qRT-PCR vs. ELISA.
MZC Protects Macaque Vaginal Mucosa Against SHIV-RT and HSV-2 Coinfection
Stimulated vaginal explants were cochallenged with SHIV-RT (10 4 TCID 50 /explant) based on our published data 36, 40, 51 and with HSV-2 (10 6 pfu/explant) based on titration experiments demonstrating robust infection with this challenge dose (not shown). Controls included cochallenged tissues cultured in the presence of 3TC and Acyclovir. Figure 2A provides representative examples of SHIV-RT and HSV-2 growth curves. Reproducible tissue infection was achieved with both viruses (Fig. 2B) . In this system, no enhancement of SHIV-RT infection was detected in the presence of HSV-2 compared with SHIV-RT alone.
We previously demonstrated that MZC gel is active against single SHIV-RT infection in PHA/IL-2-stimulated vaginal explants. 36 In this study, we aimed to determine whether MZC is active against SHIV and HSV-2 in a highdose SHIV-RT/HSV-2 cochallenge model. Stimulated tissues were exposed to SHIV-RT and HSV-2 in the presence of nontoxic (Fig. 3A) 1:100 or 1:300 diluted MZC or CG (placebo) gel. Of note, one outlier in 1:100 MZC group was detected by MTT assay (Fig. 3A) . The outlier was not excluded from the analysis as the data from explants in medium and CG 1:100 groups from the same donor were within the viable range.
To allow a direct comparison with our previous work on MZC in the single infection model, 36 p27 ELISA was used as a readout. MZC (1:100 and 1:300 dilutions) strongly inhibited SHIV-RT infection relative to untreated (medium) and CG controls (SOFT/CUM, 90%-99% inhibition, P , 0.0001/0.05) (Fig. 3B) . MZC and CG at 1:100 dilution (SOFT/CUM, 99% inhibition, P , 0.0001) and CG at 1:300 dilution (SOFT/CUM, .90% inhibition, P , 0.05) inhibited HSV-2 vs. untreated control, pointing to CG-mediated activity of MZC against HSV-2. 
MZC Protects Rectal Mucosa Against SHIV-RT Infection
Rectal biopsies were cochallenged with 10 4 TCID 50 SHIV-RT and HSV-2 10 3 -10 6 pfu per biopsy vs. 3TC/Acyclovir controls. The SHIV-RT challenge dose was chosen based on studies in vaginal tissues (above) and resulted in reproducible SHIV-RT infection (Fig. 1) . In contrast, no productive HSV-2 infection was detected in rectal mucosa as similar HSV pol copy numbers were detected in cultures with and without Acyclovir. A differential with Acyclovir control was observed only in 1 out of 10 experiments using 10 6 pfu challenge dose (not shown). We chose to test gel activity in the SHIV-RT (10 4 TCID 50 ) and HSV-2 (10 6 pfu) cochallenge settings to mimic possible real-life HIV-1/HSV-2 coexposure scenario.
Tissues were challenged in the presence of nontoxic (Fig. 4A) 1:100 dilution of MZC for 4 hours vs. untreated (medium), CG, and 3TC/Acyclovir controls. MZC afforded significant protection against SHIV-RT relative to untreated and CG controls (SOFT/CUM, 92%-98% inhibition, P , 0.0001) (Fig. 4B) . Similar anti-SHIV-RT activity (SOFT/ CUM, 97%-98% inhibition, P , 0.0001) was detected by analysis of the same data set by qRT-PCR (not shown). As expected, HSV-2 failed to infect the rectal tissues (not shown).
DISCUSSION
In this study, we introduced ex vivo vaginal SHIV-RT/ HSV-2 coinfection and rectal SHIV-RT infection models. These models were used to test MZC's activity. We also explored methodological aspects of monitoring tissue infection ex vivo. Here we compared the sensitivity of SIV gag one-step qRT-PCR and p27 ELISA methods to monitor SHIV-RT infection in vaginal and rectal explants.
A recent study by Rollenhagen et al 55 55 In contrast to data in human cervical tissue, no enhancement of SHIV-RT infection by HSV-2 in stimulated macaque vaginal mucosa was seen in the current study. The same result was obtained when unstimulated tissues were cochallenged with the same viral doses (not shown). It is worth pointing out that in this study and in the human ectocervical A more physiologically relevant, low-dose SHIV-RT/HSV-2 cochallenge model would be needed to explore whether and how coinfection drives mucosal SHIV-RT infection in macaques. We were unable to infect rectal mucosa with HSV-2 ex vivo. In vivo rectal HSV-2 infection was previously reported in 9 out of 11 SIV-infected macaques that were challenged rectally with 2 · 10 8 pfu HSV-2. 19 However, in naive animals, the frequency of infection after the same-dose HSV-2 challenge is 55%. 61 As epithelial cells represent the primary target for HSV-2, loss of the single-layer columnar epithelium during the culture period 42 could have contributed to the lack of ex vivo infection in rectal biopsies.
Our side-by-side comparison indicates that 1-step SIV gag qRT-PCR using tissue culture supernatants can be used as an alternative to p27 ELISA to monitor tissue infection and product activity. The data indicate similar SHIV-RT growth kinetics and MZC activity as detected by both assays. The 1-step SIV gag qRT-PCR has proven to be a more sensitive method than p27 ELISA. Our results are in agreement with the findings of Janocko et al, 62 who demonstrated the feasibility of qRT-PCR as a readout of HIV infection. 62 Also in agreement with this report, 62 qRT-PCR did not shorten the time to detect evidence of infection. Overall, the qRT-PCR approach offers increased sensitivity and high dynamic range. The assay requires only a small volume of the supernatant (5 mL) and is time and cost effective.
MZC gel protected against SHIV-RT at 1:100 (;0.18 mg/ mL MIV-150) and 1:300 (;0.06 mg/mL MIV-150) dilutions and against HSV-2 at 1:100 dilution in vaginal mucosa. The activity against HSV-2 was CG mediated. Similarly, the gel at 1:100 dilution also protected against SHIV-RT in rectal mucosa. It is important to note that previous studies demonstrated that the combination of CG and zinc acetate results in antiviral synergy against HSV-2. 47 The HSV-2 mouse model has shown that under stringent conditions, the combination of CG and zinc protects significantly while CG alone does not protect against HSV-2 infection. 31, 47, 63 The use of undiluted formulations in a mouse model allowed to appreciate the advantage of the CG/ zinc combination when compared with CG alone. In our explant system, CG alone provides strong inhibition (even after diluting the gel) that masks zinc's contribution.
The results demonstrating potent activity of MZC against coinfection of vaginal mucosa with SHIV-RT and HSV-2 add to our previously published data showing potent MZC's activity against single-cell-free or cell-associated SHIV-RT challenge of macaque vaginal mucosa. 36, 37 These results are also consistent with the potent activity of MZC against coinfection with HIV-1 BaL 
